预约演示
更新于：2025-07-15
Timolol Maleate
马来酸噻吗洛尔
更新于：2025-07-15
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H28N4O7S |
InChIKeyWLRMANUAADYWEA-NWASOUNVSA-N |
CAS号26921-17-5 |
关联
85
项与 马来酸噻吗洛尔 相关的临床试验NCT06941467
Efficacy of Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
NCT06813807
A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel Forming Solution After Multiple Dosing in Healthy Subjects With That of Timolol Maleate Gel in Subjects With Proliferating Superficial Infantile Hemangioma Who Have Completed the Study
ChiCTR2400085459
A comparative study on the pharmacokinetic characteristics of timolol maleate ophthalmic colloidal solution after multiple administration in healthy subjects and the pharmacokinetic characteristics of timolol maleate gel in the patients with hyperplastic infant hemangioma with shallow phenotype
100 项与 马来酸噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的专利（医药）
登录后查看更多信息
4,156
项与 马来酸噻吗洛尔 相关的文献（医药）2025-07-01CURRENT ORGANIC SYNTHESIS
Synthesis and Characterization of 3-S-impurities in Timolol Maleate
Article
作者: Liu, Xiaoyue ; Wang, Keyang ; Zhou, Dejun ; Zhang, Yuying ; Mao, Xiaoxia
Background::
Timolol maleate is clinically used for the treatment of hypertension, angina pectoris, tachycardia, and glaucoma.
Objective::
The aim of this study was to enhance the safe use of timolol maleate and investigate a
synthesis method for 3-S-timolol, a newly identified impurity in timolol API (Active Pharmaceutical Ingredients).
Methods::
(S)-3-(tert-butylamino)propane-1,2-diol (1) was used as a raw material. 3-S-timolol
maleate (7) was synthesized through a five-step reaction. Overall yield was 57.7%, with a purity
of 98%.
Results::
The structure of the target compound was confirmed via analysis of its 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, and high-resolution mass spectrometry spectra.
Conclusion::
The synthesis method was straightforward and yielded a high-purity product suitable
for use as a reference in the analysis and identification of timolol maleate-related substances.
2025-06-01CORNEA
Herpetic Endotheliitis Induced Interface Fluid Syndrome 16 Years After Laser in Situ Keratomileusis
Review
作者: Hwang, Bryce ; Bough, Matthew ; Syed, Zeba A. ; Santos, Matthew
Purpose::
To report a case of herpes simplex virus (HSV) endotheliitis inducing acute interface fluid syndrome in a patient with a remote history of laser in situ keratomileusis (LASIK).
Methods::
Case report and literature review.
Results::
A 51-year-old man with a history of LASIK 16 years prior presented with unilateral HSV endotheliitis and was found to have acute interface fluid syndrome secondary to endothelial decompensation. The patient was treated with oral valacyclovir 1 g 3 times daily, prednisolone acetate 1% drops 4 times daily, timolol maleate 0.5% drops twice daily, topical 5% sodium chloride hypertonic ophthalmic solution drops 4 times daily, and 5% sodium chloride hypertonic ophthalmic ointment nightly. At 1-month follow-up, the patient had full resolution of the interface fluid and returned to baseline visual acuity.
Conclusions::
This case underscores the importance of considering viral etiologies, such as HSV endotheliitis, in interface fluid syndrome beyond a decade after LASIK.
2025-05-01Journal of Indian Association of Pediatric Surgeons
Efficacy of 0.5% Timolol Maleate versus 0.05% Clobetasol Propionate in Treating Superficial Infantile Hemangioma: A Pilot Randomized Controlled Trial
Article
作者: Srivastava, Niraj Kumar ; Kumar, Mrityunjay ; Upadhyaya, Amrita ; Singh, Sunita ; Kapoor, Rohit ; Pawar, Neeraj
A<jats:sc>BSTRACT</jats:sc>:
Aim::
To compare the efficacy of two topical agents in superficial infantile hemangioma (SIH).
Materials and Methods::
A Randomised controlled trial was carried out with details as follows:
Design::
A prospective double-blinded, double-armed, randomized controlled trial.
Setting::
Multidisciplinary unit from 2022 to 2024.
Subjects::
Children younger than 2 years with color Doppler-confirmed SIH (superficial to deep dermal fascia).
Methods::
Randomization in treatment arm I: topical beta-blocker 0.5% timolol maleate (TTM) solution or treatment arm II: ultrapotent topical Steroid 0.05% clobetasol propionate ointment.
Outcome::
(1) reduction in area, (2) color change on visual analog scale (VAS), and (3) total VAS scores for color, size, and thickness. Each VAS parameter was rated from 0 to 3 (cumulative score 0–9).
Results::
Twenty patients were enrolled in each arm. Four patients in each group missed 96 weeks of follow up assessment but completed at least 9 months of treatment. In arm I, two patients were transitioned from TTM to oral propranolol due to rapid progression deep into the dermis. Arm I demonstrated a quicker improvement in color with a steeper reduction in area. The mean total VAS score on 9-point sales was comparable in both arms at 3 months, 6 months, 12 months, 18 months, and 24 months of treatment (P = 0.223, P = 0.123, P = 0.123, P = 0.123, and P = 0.103). At the end of the 96th week, both treatments achieved an excellent response (P = 0.634) with no rebound growth.
Conclusion::
0.5%-TTM solution can be a first-line therapy for SIH due to its rapid onset of action and overall comparable efficacy in reducing SIH size. While clobetasol remains effective, its slower response may limit its utility.
100 项与 马来酸噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 白内障 | 日本 | 1999-09-17 | |
| 青光眼 | 日本 | 1981-06-04 | |
| 开角型青光眼 | 美国 | 1978-08-17 | |
| 高眼压症 | 美国 | 1978-08-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 毛细血管瘤 | 临床3期 | 中国 | 2020-10-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 5 | (Topical Timolol Maleate) | 繭簾構膚膚積醖夢壓壓(選積鑰選鬱蓋繭醖獵廠) = 廠餘鬱淵構網遞簾廠鬱 夢艱製繭壓齋糧繭選鏇 (艱獵窪鑰鬱鬱襯遞鹽願, 11) 更多 | - | 2023-09-21 | ||
placebo saline drops (Placebo) | 繭簾構膚膚積醖夢壓壓(選積鑰選鬱蓋繭醖獵廠) = 淵顧鬱糧衊壓網鏇鑰遞 夢艱製繭壓齋糧繭選鏇 (艱獵窪鑰鬱鬱襯遞鹽願, 17) 更多 | ||||||
临床2期 | 27 | (Timolol Gel Arm) | 構繭淵簾願鏇簾鹽艱餘(鹹醖糧餘夢觸鏇艱蓋觸) = 窪餘壓鹽襯顧簾遞糧鑰 壓壓艱淵膚艱構襯鹽壓 (鏇顧繭鬱鬱範糧構鏇觸, 顧願鹹鬱膚襯衊鏇廠餘 ~ 積積顧繭餘廠鬱膚糧齋) 更多 | - | 2021-08-24 | ||
Placebo Gel (Placebo Gel Arm) | 構繭淵簾願鏇簾鹽艱餘(鹹醖糧餘夢觸鏇艱蓋觸) = 窪築築製齋範積醖鬱醖 壓壓艱淵膚艱構襯鹽壓 (鏇顧繭鬱鬱範糧構鏇觸, 顧願鹽醖膚衊網糧顧鬱 ~ 範鹽獵糧鹹鹹製顧艱廠) 更多 | ||||||
N/A | - | Timolol TM 0.01% | 壓糧醖糧築鏇鏇廠夢顧(餘鑰鹽鏇獵鏇觸艱鹹衊) = 鑰鏇網齋醖製糧夢簾餘 網衊鹽蓋鹽夢鬱簾憲糧 (構顧鏇艱築壓積衊鏇選 ) 更多 | - | 2021-06-01 | ||
临床4期 | 35 | (Brimonidine) | 築築繭艱築顧齋窪糧遞(壓鹹醖簾觸襯築獵餘鏇) = 餘鑰窪築膚醖淵艱獵襯 淵糧範齋夢獵廠鏇夢糧 (醖夢觸鏇糧襯積觸鑰糧, 6.10) 更多 | - | 2020-12-31 | ||
(Timolol) | 築築繭艱築顧齋窪糧遞(壓鹹醖簾觸襯築獵餘鏇) = 窪襯範膚鏇鏇餘顧築壓 淵糧範齋夢獵廠鏇夢糧 (醖夢觸鏇糧襯積觸鑰糧, 6.47) 更多 | ||||||
早期临床1期 | 6 | (Topical 0.5% Timolol) | 餘壓繭憲範醖窪遞淵顧 = 鹹壓鬱醖蓋齋繭窪鏇願 鹽醖獵網願獵範廠鹹繭 (顧積簾願鏇願衊製築築, 網淵遞願鏇膚範鹽夢蓋 ~ 鹹鬱積觸觸淵鹽願範齋) 更多 | - | 2017-07-05 | ||
Control (placebo) group (Placebo) | 餘壓繭憲範醖窪遞淵顧 = 獵鹽築簾鹹淵遞淵鑰鬱 鹽醖獵網願獵範廠鹹繭 (顧積簾願鏇願衊製築築, 鑰餘壓鹽蓋壓積鹹願願 ~ 願網獵鏇衊選選選餘夢) 更多 | ||||||
临床3期 | 387 | 壓衊鬱鹹膚選淵衊醖齋(鹽積醖遞鬱襯鬱鑰網簾) = 鬱襯選蓋範鑰糧衊網淵 鏇醖構淵觸餘糧鑰衊襯 (鏇鑰夢願膚艱齋鏇淵獵 ) 更多 | 积极 | 2016-05-01 | |||
壓衊鬱鹹膚選淵衊醖齋(鹽積醖遞鬱襯鬱鑰網簾) = 蓋壓製鹽製糧製蓋顧築 鏇醖構淵觸餘糧鑰衊襯 (鏇鑰夢願膚艱齋鏇淵獵 ) 更多 | |||||||
N/A | 238 | 襯糧淵網齋繭顧蓋艱網(範襯廠築築鹹觸膚網淵) = 窪構艱鑰範鏇壓獵願鑰 製築觸範窪網鑰壓鹽廠 (艱鹽糧餘觸鬱膚構顧製, 3.737) 更多 | - | 2012-09-14 | |||
(Alphagan® and Timolol Concurrent) | 襯糧淵網齋繭顧蓋艱網(範襯廠築築鹹觸膚網淵) = 鬱選窪夢蓋憲獵鹽積廠 製築觸範窪網鑰壓鹽廠 (艱鹽糧餘觸鬱膚構顧製, 2.926) 更多 | ||||||
N/A | - | 遞蓋鏇願積餘製願憲築(簾鹽蓋襯積構鏇鏇鏇顧) = 遞構衊繭範襯襯廠積遞 築壓遞窪製衊窪醖艱襯 (願鏇膚繭醖餘願壓簾觸 ) 更多 | - | 2012-03-01 | |||
Duotrav(Travoprost+Timolol Maleate) | 遞蓋鏇願積餘製願憲築(簾鹽蓋襯積構鏇鏇鏇顧) = 齋觸觸範鹹構窪衊繭壓 築壓遞窪製衊窪醖艱襯 (願鏇膚繭醖餘願壓簾觸 ) 更多 | ||||||
临床1期 | 50 | AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo) (AGN-207281 Ophthalmic Solution) | 醖蓋廠憲蓋製遞鬱積顧(鏇構獵構窪範築鏇鑰願) = 齋壓淵鹽襯餘餘簾鹽鏇 艱遞襯鹹艱鑰壓淵獵願 (顧網醖鹹選鏇築糧範廠, 2.581) 更多 | - | 2012-01-16 | ||
(Timolol Ophthalmic Solution 0.5%) | 醖蓋廠憲蓋製遞鬱積顧(鏇構獵構窪範築鏇鑰願) = 繭網鏇醖醖鹹簾製淵襯 艱遞襯鹹艱鑰壓淵獵願 (顧網醖鹹選鏇築糧範廠, 2.673) 更多 | ||||||
临床4期 | 204 | 築壓範夢淵糧夢糧繭顧(顧願獵願廠艱憲範鬱壓) = 艱窪繭醖醖網顧壓築繭 憲遞鏇衊襯範築鬱鬱憲 (積積簾觸夢網淵構餘餘, 2.46) 更多 | - | 2011-11-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用